Navigation Links
FDA Identifies Contaminant in Blood-Thinning Drug
Date:3/19/2008

Chemically altered form of natural compound found in heparin samples

WEDNESDAY, March 19 (HealthDay News) -- U.S. health officials say they've identified the contaminant found in the blood-thinner heparin, which has been linked to hundreds of allergic reactions and possibly 19 deaths in the United States.

The contaminant is a man-made chemical called oversulfated condroitin sulfate, but U.S. Food and Drug Administration officials could not say Wednesday how it got into the heparin. And they're not even sure it's to blame for the allergic reactions and deaths.

But Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said the oversulfated condroitin sulfate was the only contaminant found in samples of the blood thinner, which was produced in China for Baxter Healthcare Corp., based in Deerfield, Ill.

Oversulfated chondroitin sulfate mimics heparin's qualities and is a modified form of chondroitin sulfate. Chondroitin sulfate is a naturally occurring substance made from animal cartilage and is often used in supplements to treat arthritic joints. But, oversulfated chondroitin sulfate is man-made and doesn't occur naturally.

"It is most likely that chondroitin sulfate was chemically modified to create this compound," Woodcock said during a teleconference. "Oversulfated chondroitin sulfate, unlike common chondroitin sulfate, mimics heparin's activity, therefore appears to be heparin when subjected to standard tests."

The contaminant was found in samples of heparin that the FDA tested from Scientific Protein's Changzhou SPL plant in China, which supplied Baxter with the active ingredient in heparin, Woodcock said. It was also found in Baxter's heparin products in the United States, she said.

"Testing of these samples suggests that the contaminant accounted for approximately 2 to 50 percent of the total content of the active pharmaceutical ingredient in some of these samples," Woodcock said.

Woodcock said that the FDA doesn't know if the contaminant wound up in the heparin deliberately or by accident, and that the agency was trying to answer that question. But, she noted that oversulfated chondroitin sulfate is less expensive than the active pharmaceutical ingredient in heparin.

"Still to be determined is whether or not oversulfated chondroitin sulfate, when combined with heparin, can produce the serious allergic reactions of the sort reported to Baxter and FDA," Woodcock said.

Heparin is often given to dialysis patients and people undergoing heart surgery. The raw materials for the drug come from the mucous lining of pig intestines. Many of those pigs come from rural farms in China, with the intestines often processed by unregulated mom-and-pop workshops before further processing at Scientific Protein's plant in Changzhou.

The reported adverse reactions have included difficulty breathing, nausea or vomiting, excessive sweating and falling blood pressure, which can lead to life-threatening shock.

Since the end of December, there have been 785 reports of allergic reactions associated with Baxter's heparin. This compares with fewer than 100 reports of adverse reactions in all of 2007.

There also have been 46 deaths among heparin users, 19 possibly linked to the drug and four more conclusively so, according to the FDA.

However, since the lots of Baxter's heparin were recalled Feb. 28, no new deaths have been reported, Woodcock said.

Woodcock added that the FDA has been testing imported heparin entering the United States since March 14.

"Doctors and patients now can be confident that the product on the market has been tested and is safe," she said.

More information

For more on heparin, visit the U.S. National Library of Medicine.



SOURCE: March 19, 2008, teleconference with Janet Woodcock, M.D., director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Iowa State University researcher identifies eye disease in canines
2. Study identifies reasons patients referred late to nephrologists
3. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
4. Study identifies another strategy for normalizing tumor blood supply
5. Math model identifies key to controlling epidemic
6. Study identifies which men are likely to have persistent prostate cancer
7. UCSD research team identifies novel anticancer drug from the sea
8. New Report Identifies Health Disparities and Reduction Strategies
9. Carnegie Mellon study identifies where thoughts of familiar objects occur inside the human brain
10. Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
11. New neuroimaging study identifies brain signature for cigarette cravings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical health ... patients with dental emergencies at risk of losing a tooth or their smiles. Dr. ... , Common dental emergencies include:, , Avulsed or knocked-out teeth ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron ... accepting new dental patients and families in the North Metro Denver area. The new ... cleanings to cosmetic dentistry, and all in the most relaxing environment. , While some ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Rich Pharmaceuticals, ... today announced a 1-for-100 reverse split of its issued ... opening of trading on Thursday, February 11, 2016. The ... under new CUSIP number 76303T308 and temporary ticker symbol ... commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
Breaking Medicine Technology: